We read with interest the report by O'Rourke et al,1 and there are some controversial data that are important to analyze. Reading this report, one could think that only one product of low-molecular-weight (LMW) heparin (enoxaparin sodium) is available in the treatment of acute coronary syndromes or that enoxaparin is better than the other LMW heparin products. However, there are 3 available LMW heparin products for this treatment (dalteparin, nadroparin, and enoxaparin), and there are no differences in their applications according to the current guidelines of cardiology.2
Borja J, Paz MA, Olivella P. New Approaches to Diagnosis and Management of Unstable Angina and Non–ST Segment Elevation Myocardial Infarction: Controversial Data. Arch Intern Med. 2002;162(4):485–486. doi:
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.